Canaccord Genuity Group Issues Pessimistic Forecast for TriSalus Life Sciences (NASDAQ:TLSI) Stock Price

TriSalus Life Sciences (NASDAQ:TLSI) had its target price reduced by research analysts at Canaccord Genuity Group from $12.00 to $11.00 in a report released on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 187.96% from the company’s previous close.

Several other brokerages have also commented on TLSI. Roth Mkm initiated coverage on shares of TriSalus Life Sciences in a research report on Monday. They set a “buy” rating and a $11.00 price target for the company. Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Monday. Northland Securities began coverage on shares of TriSalus Life Sciences in a research report on Friday, October 25th. They set an “outperform” rating and a $12.50 price target on the stock. Finally, Oppenheimer began coverage on TriSalus Life Sciences in a research note on Monday, September 16th. They set an “outperform” rating and a $10.00 target price for the company. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $12.08.

TriSalus Life Sciences Stock Down 4.7 %

NASDAQ TLSI opened at $3.82 on Friday. The firm has a 50 day moving average of $4.38 and a two-hundred day moving average of $5.85. The stock has a market capitalization of $116.47 million, a PE ratio of -1.60 and a beta of 0.49. TriSalus Life Sciences has a 52 week low of $3.32 and a 52 week high of $10.42.

TriSalus Life Sciences (NASDAQ:TLSI) last released its earnings results on Wednesday, August 14th. The company reported ($0.21) EPS for the quarter. The firm had revenue of $7.36 million for the quarter. On average, equities research analysts expect that TriSalus Life Sciences will post -1.5 earnings per share for the current fiscal year.

Insider Activity at TriSalus Life Sciences

In other TriSalus Life Sciences news, CEO Mary T. Szela acquired 7,520 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was acquired at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the acquisition, the chief executive officer now directly owns 377,382 shares in the company, valued at $1,962,386.40. This represents a 2.03 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 32.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of TLSI. Highbridge Capital Management LLC bought a new position in TriSalus Life Sciences during the second quarter worth about $1,184,000. Wolverine Asset Management LLC bought a new stake in TriSalus Life Sciences in the second quarter worth $240,000. Duquesne Family Office LLC increased its holdings in shares of TriSalus Life Sciences by 35.1% in the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after buying an additional 110,966 shares during the period. Walleye Capital LLC purchased a new stake in TriSalus Life Sciences during the 3rd quarter valued at about $66,000. Finally, MSD Partners L.P. bought a new stake in TriSalus Life Sciences in the third quarter valued at approximately $184,000. 2.58% of the stock is owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.